Abstract | PURPOSE: PATIENTS AND METHODS: Between August 1989 and November 2006, 47 patients with gallbladder cancer underwent surgical resection followed by adjuvant radiotherapy. There were 21 males and 26 females, and median age was 60 years (range 44-75 years). Postoperative radiotherapy was delivered to the tumor bed and regional lymph nodes up to 40-50 Gy at 2 Gy/fraction; 41 patients also received intravenous 5-fluorouracil as a radiosensitizer. Median follow-up duration was 48 months for survivors. RESULTS: There were 2 isolated locoregional recurrences, 14 isolated distant metastases, and 7 combined locoregional and distant relapses. The 5-year overall survival rate was 43.7%. According to the extent of resection, the 5-year overall survival rates were 52.8%, 20.0%, and 0% in R0-, R1-, and R2-resected patients, respectively (p = 0.0038). On multivariate analysis incorporating extent of resection, T stage, N stage, performance of lymph node dissection, and histologic differentiation, extent of resection was the only prognostic factor associated with overall survival (p = 0.0075). Among the 37 patients with R0 resection, there was no difference of 5-year overall survival rates in patients with N0, N1, and Nx diseases (46.2%, 60.0%, and 44.4%, respectively, p = 0.6246). As for significant treatment-related morbidity, there was only 1 patient with grade 4 gastric ulcer. CONCLUSION:
|
Authors | K Kim, E K Chie, J-Y Jang, S W Kim, S-W Han, D-Y Oh, S-A Im, T-Y Kim, Y-J Bang, S W Ha |
Journal | Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]
(Strahlenther Onkol)
Vol. 188
Issue 5
Pg. 388-92
(May 2012)
ISSN: 1439-099X [Electronic] Germany |
PMID | 22402869
(Publication Type: Journal Article)
|
Chemical References |
- Radiation-Sensitizing Agents
- Fluorouracil
|
Topics |
- Adenocarcinoma
(mortality, pathology, surgery, therapy)
- Adult
- Aged
- Chemoradiotherapy
- Female
- Fluorouracil
(therapeutic use)
- Gallbladder Neoplasms
(mortality, pathology, surgery, therapy)
- Humans
- Male
- Middle Aged
- Radiation-Sensitizing Agents
(therapeutic use)
- Radiotherapy, Adjuvant
- Retrospective Studies
- Survival Analysis
|